CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 57 enrolled
Drug / intervention
Gemcitabine plus PM060184drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02533674
NCT02533674Phase 1Completed

Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors

PharmaMar·interventional·Posted Aug 27, 2015·Updated Jun 11, 2021

In Brief

A Phase 1 clinical trial evaluating Gemcitabine plus PM060184 for Solid Tumors. Completed, enrolled 57 participants across 2 sites in 2 countries.

Detailed Summary

Prospective, open-label, dose-ranging, uncontrolled phase I study with escalating doses of PM060184 in combination with gemcitabine in selected patients with advanced solid tumors. The study objectives are: To determine the MTD and the RD of PM060184 in combination with gemcitabine in selected patients with advanced solid tumors. To characterize the safety profile and feasibility of this combination in this study population. To characterize the pharmacokinetics of this combination and to detect major drug-drug PK interactions. To obtain preliminary information on the clinical antitumor activity of this combination.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumors
CountriesSpain, United States
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 27, 2015
Enrollment StartDec 12, 2014
Primary CompletionJul 11, 2019
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 10.8 years ago

Interventions

Gemcitabine plus PM060184drug